Navigation Links
Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
Date:12/17/2008

MUMBAI, India, Dec. 17 /PRNewswire/ -- Pharma Major, Lupin Ltd. announced today that it has settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough's "Clarinex"(R) tablets.

As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances.

Lupin had earlier filed a Paragraph IV certification to, among others, U.S. Patent Nos. 6,100,274, 7,214,683 and 7,214,684, contesting that these patents were either invalid or had not been infringed upon - resulting in the subsequent litigation by Schering Corp. and Sepracor.

Schering-Plough's Clarinex(R) tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.

Commenting on the settlement, Dr. Kamal Sharma, Managing Director, Lupin said - "The settlement with Schering-Plough leaves us strategically poised to further strengthen, consolidate and grow our market position in the U.S. markets. Furthermore, the settlement, recent product approvals and growth in filings across markets are a testament to our increased strengths and focus on Research & Development and the quality of our Intellectual property - a testimony to Lupin's larger goal of developing and delivering quality, cost-effective drugs for everybody."

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders. For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million), respectively.

    BSE : 500257    NSE: Lupin    REUTERS: LUPN.BO    BLOOMBERG:LPC IN

    For further information contact: 

    Shamsher Gorawara
    Head - Corporate Communications
    Lupin Limited
    Mobile: +91 9820338555
    shamshergorawara@lupinpharma.com 

    OR

    Archana Pradhan
    Escher PR
    Tel. +91 22 24901327, 24901328
    Mobile: +91 9820330505
    archana@escherpr.com


'/>"/>
SOURCE Lupin Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
2. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
3. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
4. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
5. Lupin Launches Ramipril Capsules
6. Lupin Receives USFDA Approval for Topiramate Tablets
7. Dynatronics Announces Changes to Board and Launches Operational Improvement Process
8. SantaFe Senior Living Announces Leadership Transition
9. Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM
10. Finesse Announces TruDO Optical Autoclavable Sensors for Bioprocess Applications
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... City, FL (PRWEB) , ... June 24, 2016 , ... ... inflammation common after venous procedures, dermaka cream can be incorporated into the post-surgical treatment ... and minor surgical procedures. , dermaka cream is very effective for bruising and ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located ... famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat ... Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
Breaking Medicine Technology: